Success Metrics

Clinical Success Rate
81.0%

Based on 17 completed trials

Completion Rate
81%(17/21)
Active Trials
4(13%)
Results Posted
94%(16 trials)
Terminated
4(13%)

Phase Distribution

Ph phase_2
5
16%
Ph not_applicable
1
3%
Ph phase_1
3
10%
Ph phase_3
17
55%
Ph phase_4
3
10%
Ph early_phase_1
2
6%

Phase Distribution

5

Early Stage

5

Mid Stage

20

Late Stage

Phase Distribution31 total trials
Early Phase 1First-in-human
2(6.5%)
Phase 1Safety & dosage
3(9.7%)
Phase 2Efficacy & side effects
5(16.1%)
Phase 3Large-scale testing
17(54.8%)
Phase 4Post-market surveillance
3(9.7%)
N/ANon-phased studies
1(3.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.8%

17 of 24 finished

Non-Completion Rate

29.2%

7 ended early

Currently Active

4

trials recruiting

Total Trials

31

all time

Status Distribution
Active(5)
Completed(17)
Terminated(7)
Other(2)

Detailed Status

Completed17
Terminated4
Withdrawn3
Active, not recruiting2
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
4
Success Rate
81.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (6.5%)
Phase 13 (9.7%)
Phase 25 (16.1%)
Phase 317 (54.8%)
Phase 43 (9.7%)
N/A1 (3.2%)

Trials by Status

unknown13%
not_yet_recruiting13%
suspended13%
active_not_recruiting26%
recruiting26%
completed1755%
withdrawn310%
terminated413%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT06430801Phase 3

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Recruiting
NCT04246177Phase 3

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Completed
NCT06052059Phase 3

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Active Not Recruiting
NCT06961708Phase 1

A Study of Fosmanogepix in Healthy Adult Chinese Subjects

Completed
NCT04524273Phase 3

Myasthenia Gravis Inebilizumab Trial

Active Not Recruiting
NCT03257319Phase 3

Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department

Completed
NCT06039566Phase 3

NAC vs Placebo on Opioid Use for Hysterectomy

Recruiting
NCT05757544Phase 2

Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

Withdrawn
NCT06266221Phase 3

Severe Erythema Multiforme - CORTICO

Not Yet Recruiting
NCT03557684Early Phase 1

Leucine for Depression Study (L-DEP)

Terminated
NCT03751423Phase 3

Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion

Suspended
NCT03553498Phase 3

IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients

Completed
NCT03277248Phase 3

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Completed
NCT03277261Phase 3

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Completed
NCT04309877Early Phase 1

Theophylline for Depression Study

Withdrawn
NCT02351700Phase 4

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

Completed
NCT00864097Phase 3

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

Terminated
NCT02036645Phase 1

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Completed
NCT02549716Phase 4

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

Terminated
NCT00315913Phase 2

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

Withdrawn

Drug Details

Intervention Type
OTHER
Total Trials
31